Abstract
Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Current Drug Targets
Title: Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy
Volume: 5 Issue: 1
Author(s): Joseph Torresi, Mandvi Bharadwaj, David C. Jackson and Eric J. Gowans
Affiliation:
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Abstract: Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Export Options
About this article
Cite this article as:
Torresi Joseph, Bharadwaj Mandvi, Jackson C. David and Gowans J. Eric, Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy, Current Drug Targets 2004; 5 (1) . https://dx.doi.org/10.2174/1389450043490677
DOI https://dx.doi.org/10.2174/1389450043490677 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Aptamers and New Bioreceptors for the Electrochemical Detection of Biomarkers Expressed in Hepatocellular Carcinoma
Current Medicinal Chemistry Current Management of Chordoma
Current Drug Therapy Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges
Current Cancer Drug Targets Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain
Current Medicinal Chemistry Keratin 18, Apoptosis, and Liver Disease in Children
Current Pediatric Reviews Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Patent Selections :
Recent Patents on Biomarkers MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Nanoparticulated Polymeric Systems for Gene Delivery
Current Pharmaceutical Design Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets p38 MAP Kinase Interacts with and Stabilizes Pancreatic and Duodenal Homeobox-1
Current Molecular Medicine Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease
Current Drug Targets